What are the most valued startups in the Brain-Computer interface market?

Last updated: 13 July 2026

Download our beautiful pitch about the Brain-Computer interface market

In our updated market reports, you will find everything you need

The Brain-Computer interface market includes implantable neural systems, non-invasive interfaces, EEG platforms, neuromodulation devices, and brain-data software.

This ranking tracks 99 companies and compares their latest reported or estimated valuations.

We update the list every month as funding rounds, public market prices, acquisitions, and new company disclosures become available.

And if you want to better understand this new industry, you can download our pitch covering the Brain-Computer interface market.

A quick summary table

Metric	Value
Most valuable Brain-Computer interface startup	Neuralink, $9.0B–$10.0B
Second most valuable Brain-Computer interface startup	Science Corporation, $1.5B
Median Brain-Computer interface startup valuation	Approximately $60M
Share of Brain-Computer interface valuation captured by the top 10	Approximately 64%
Top Brain-Computer interface valuation versus median	Approximately 158 times
Median valuation-to-capital-raised ratio	Approximately 3.6 times
Brain-Computer interface startups valued at $1B+	3, or 4 including Synchron at the top of its range

Top startups in the Brain-Computer interface market ranked by valuation

Here is an updated table that ranks the top startups in the Brain-Computer interface market based on their latest reported or estimated valuations.

If you want more detaild about their fundraising activity, you can check our list of the startups who have raised the most funding in the Brain-Computer interface market.

#	Startup Name	What They Do	Current Valuation ($)	Valuation Confidence Level	Valuation Type	Evidence Status	Total Funding ($)	Funding Confidence Level
1	Neuralink	Implantable BCI chips	$9.0B–$10.0B	Strong Confidence	Announced Private Round Valuation	Observed	$1.2B	Strong Confidence
2	Science Corporation	Retinal and neural implants	$1.5B	Strong Confidence	Announced Private Round Valuation	Observed	$385M	Partial Confidence
3	BrainCo	Wearable and prosthetic BCI	$1.3B–$1.6B	Partial Confidence	IPO or Listing Range Valuation	Estimated	$292M	Strong Confidence
4	Synchron	Endovascular BCI implant	$900M–$1.0B	Strong Confidence	Announced Private Round Valuation	Observed	$325M	Partial Confidence
5	Merge Labs	Non-invasive AI brain interface	$850M	Strong Confidence	Announced Private Round Valuation	Observed	$252M	Strong Confidence
6	Cognito Therapeutics	Alzheimer’s sensory stimulation therapy	$700M–$900M	Strong Confidence	Implied Valuation from Raise	Implied	$233M	Partial Confidence
7	Beacon Biosignals	AI-powered EEG biomarker platform	$650M–$950M	Strong Confidence	Implied Valuation from Raise	Implied	$132M	Strong Confidence
8	Ceribell	Rapid EEG seizure detection	$740M	Full Confidence	Public Market Cap	Observed	$318M	Strong Confidence
9	Neurophos	Photonic AI computing processors	$550M–$920M	Strong Confidence	Implied Valuation from Raise	Implied	$118M	Full Confidence
10	Nudge	Non-invasive whole-brain ultrasound interface	$500M–$750M	Strong Confidence	Implied Valuation from Raise	Implied	$100M	Full Confidence
11	StairMed	Implantable BMI and DBS	$480M–$730M	Partial Confidence	Implied Valuation from Raise	Implied	$121M	Partial Confidence
12	NeuroPace	Responsive epilepsy neurostimulation	$572M	Full Confidence	Public Market Cap	Observed	$338M	Partial Confidence
13	Neuracle	EEG and BCI systems	$520M–$580M	Strong Confidence	IPO or Listing Range Valuation	Estimated	$36M+	Low Confidence
14	Precision Neuroscience	Minimally invasive cortical implant	$500M–$600M	Strong Confidence	Announced Private Round Valuation	Observed	$155M	Full Confidence
15	Neuros Medical	Post-amputation pain neurostimulation	$400M–$600M	Strong Confidence	Implied Valuation from Raise	Implied	$115M	Partial Confidence
16	CoMind	Non-invasive cerebral monitoring technology	$350M–$500M	Strong Confidence	Implied Valuation from Raise	Implied	$103M	Partial Confidence
17	INBRAIN Neuroelectronics	Graphene neural implant platform	$330M–$500M	Partial Confidence	Implied Valuation from Raise	Implied	$68M	Strong Confidence
18	Cala Health	Wearable tremor neuromodulation	$320M–$500M	Partial Confidence	Implied Valuation from Raise	Implied	$195M	Partial Confidence
19	Axoft	Soft implantable BCIs	$275M–$460M	Partial Confidence	Implied Valuation from Raise	Implied	$63M	Full Confidence
20	Blackrock Neurotech	Utah Array BCI systems	$350M	Strong Confidence	Acquisition Value	Observed	$247M	Partial Confidence
21	Gestala	Ultrasound BCI platform	$250M–$410M	Partial Confidence	Implied Valuation from Raise	Implied	$84M	Strong Confidence
22	Zeto	Wireless clinical EEG systems	$220M–$340M	Strong Confidence	Implied Valuation from Raise	Implied	$38M	Strong Confidence
23	Zhiran Medical / BCIFlex	Flexible implantable BCI platform	$210M–$350M	Strong Confidence	Implied Valuation from Raise	Implied	$84M	Partial Confidence
24	Omniscient Neurotechnology	AI-powered brain connectomics mapping	$230M–$320M	Strong Confidence	Implied Valuation from Raise	Implied	$87M	Strong Confidence
25	Neurable	Everyday non-invasive brain interfaces	$190M–$280M	Strong Confidence	Implied Valuation from Raise	Implied	$65M	Partial Confidence
26	Paradromics	High-bandwidth neural implant	$180M–$280M	Low Confidence	Implied Valuation from Raise	Implied	$74M	Strong Confidence
27	ONWARD Medical	Spinal cord stimulation therapies	$214M	Full Confidence	Public Market Cap	Observed	$294M	Partial Confidence
28	Aoyi Tech / OYMotion	Neural interfaces and robotic hands	$140M–$260M	Strong Confidence	Implied Valuation from Raise	Implied	$28M	Partial Confidence
29	NeuroXess	Implantable BCI systems	$120M–$220M	Low Confidence	Comparables-Based Estimate	Estimated	$44M+	Partial Confidence
30	Brainomix	AI stroke imaging software	$130M–$210M	Strong Confidence	Implied Valuation from Raise	Implied	$59M	Strong Confidence
31	Motif Neurotech	Implantable depression neuromodulation	$100M–$160M	Partial Confidence	Comparables-Based Estimate	Estimated	$19M	Full Confidence
32	Iota Biosciences	Implantable bioelectronic microdevices	$128M	Full Confidence	Acquisition Value	Observed	$15M	Strong Confidence
33	Phantom Neuro	Prosthetic control through muscle signals	$105M–$150M	Strong Confidence	Implied Valuation from Raise	Implied	$22M	Full Confidence
34	Newronika	Adaptive deep-brain stimulation systems	$95M–$150M	Partial Confidence	Implied Valuation from Raise	Implied	$25M	Full Confidence
35	Kernel	Optical brain-measurement helmets	$90M–$150M	Low Confidence	Comparables-Based Estimate	Estimated	$158M	Partial Confidence
36	Magnus Medical	Personalized depression neurostimulation	$90M–$150M	Partial Confidence	Comparables-Based Estimate	Estimated	$50M	Partial Confidence
37	Rune Labs	Precision neurology data platform	$75M–$140M	Partial Confidence	Implied Valuation from Raise	Implied	$57M	Strong Confidence
38	NextSense	EEG-enabled smart earbuds	$85M–$125M	Strong Confidence	Implied Valuation from Raise	Implied	$17M	Partial Confidence
39	Neuromod Devices	Bimodal tinnitus neuromodulation device	$80M–$125M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$46M	Strong Confidence
40	BRAIN.Q	Electromagnetic stroke recovery therapy	$75M–$120M	Low Confidence	Comparables-Based Estimate	Estimated	$49M	Strong Confidence
41	Subsense	Nanoparticle-based non-surgical brain interface	$75M–$115M	Strong Confidence	Implied Valuation from Raise	Implied	$27M	Full Confidence
42	Nia Therapeutics	Memory-restoring neural implants	$75M–$110M	Partial Confidence	Implied Valuation from Raise	Implied	$26M	Partial Confidence
43	g.tec medical engineering	Clinical BCI and EEG platforms	$75M–$105M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$0M	Partial Confidence
44	NEUROPHET	AI brain imaging analysis	$88M	Full Confidence	Public Market Cap	Observed	$78M	Partial Confidence
45	NeuraMatrix	Implantable neural interfaces	$60M–$110M	Low Confidence	Proxy-Based Estimate	Estimated	$16M	Strong Confidence
46	Epia Neuro	Implant-assisted stroke motor rehabilitation	$60M–$100M	Partial Confidence	Proxy-Based Estimate	Estimated	$0M	Low Confidence
47	Ampa Health	Portable depression stimulation therapy	$60M–$90M	Partial Confidence	Implied Valuation from Raise	Implied	$25M+	Partial Confidence
48	Synergia Medical	Optoelectronic epilepsy neurostimulation implant	$55M–$85M	Partial Confidence	Comparables-Based Estimate	Estimated	$23M	Strong Confidence
49	Arctop	Real-time brain-decoding software	$50M–$75M	Partial Confidence	Comparables-Based Estimate	Estimated	$10M	Strong Confidence
50	Neuroelectrics	EEG-guided electrical brain stimulation	$45M–$75M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$18M	Strong Confidence
51	Brain Products	Neurophysiology EEG research hardware	$45M–$75M	Partial Confidence	Proxy-Based Estimate	Estimated	$0M	Partial Confidence
52	Elemind	Neurostimulation sleep wearable	$45M–$75M	Partial Confidence	Implied Valuation from Raise	Implied	$12M	Full Confidence
53	Epiminder	Implantable epilepsy monitoring system	$57M	Full Confidence	Public Market Cap	Observed	$111M	Partial Confidence
54	Flow Neuroscience	Depression brain-stimulation headset	$40M–$65M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$12M	Strong Confidence
55	Coherence Neuro	Closed-loop neurotechnology for cancer	$40M–$65M	Strong Confidence	Implied Valuation from Raise	Implied	$10M	Strong Confidence
56	icometrix	AI neurological MRI analysis	$35M–$70M	Low Confidence	Acquisition Value	Estimated	$20M	Strong Confidence
57	Cognixion	Assistive communication neural interfaces	$40M–$55M	Partial Confidence	Comparables-Based Estimate	Estimated	$21M	Partial Confidence
58	CorTec	Implantable neural interface systems	$35M–$60M	Low Confidence	Comparables-Based Estimate	Estimated	$20M	Partial Confidence
59	Cortigent	Cortical vision-restoration implants	$40M–$55M	Partial Confidence	Acquisition Value	Implied	$36M	Partial Confidence
60	Neurosoft Bioelectronics	Soft cortical neural electrode implants	$35M–$55M	Strong Confidence	Implied Valuation from Raise	Implied	$8M	Partial Confidence
61	Emotiv	Wireless EEG headsets and software	$30M–$50M	Low Confidence	Revenue or ARR Multiple Estimate	Estimated	$7M	Partial Confidence
62	Neurovalens	Non-invasive therapeutic neurostimulation	$30M–$50M	Partial Confidence	Implied Valuation from Raise	Implied	$19M	Partial Confidence
63	Neurolief	Wearable migraine neuromodulation therapy	$30M–$45M	Partial Confidence	Implied Valuation from Raise	Implied	$19M	Partial Confidence
64	Bitbrain	EEG hardware and neurotechnology services	$28M–$45M	Low Confidence	Revenue or ARR Multiple Estimate	Estimated	$0M	Low Confidence
65	NeuroSky	Consumer EEG sensors and chips	$25M–$45M	Low Confidence	Revenue or ARR Multiple Estimate	Estimated	$18M	Partial Confidence
66	Piramidal	Foundation models for brainwaves	$28M–$40M	Partial Confidence	Implied Valuation from Raise	Implied	$6M	Full Confidence
67	BrainSightAI	AI functional brain mapping	$24M–$38M	Partial Confidence	Implied Valuation from Raise	Implied	$7M	Partial Confidence
68	ABILITY Neurotech	Fully implantable wireless ECoG interface	$20M–$40M	Low Confidence	Proxy-Based Estimate	Estimated	$0M	Low Confidence
69	NeuroBionics	Endovascular neuromodulation implant platform	$22M–$35M	Partial Confidence	Implied Valuation from Raise	Implied	$10M	Strong Confidence
70	BioSerenity	Remote EEG and sleep diagnostics	$28M	Strong Confidence	Acquisition Value	Observed	$116M	Partial Confidence
71	NeuroOne Medical Technologies	Thin-film neural electrodes	$26M	Full Confidence	Public Market Cap	Observed	$29M	Partial Confidence
72	Cumulus Neuroscience	Digital biomarkers for clinical trials	$20M–$30M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$13M	Partial Confidence
73	Forest Neurotech	Ultrasound brain imaging and stimulation	$15M–$30M	Low Confidence	Proxy-Based Estimate	Estimated	$0M	Strong Confidence
74	Neurosity	Brain-sensing productivity wearables	$15M–$25M	Low Confidence	Comparables-Based Estimate	Estimated	$5M	Partial Confidence
75	Biological Input Output Systems	Peripheral nerve prosthetic interface	$15M–$25M	Partial Confidence	Proxy-Based Estimate	Estimated	$0M	Strong Confidence
76	BrainKey	Consumer brain MRI analytics	$15M–$25M	Partial Confidence	Revenue or ARR Multiple Estimate	Estimated	$0M	Full Confidence
77	NextMind	Consumer visual brain interface	$13M–$25M	Low Confidence	Acquisition Value	Estimated	$5M	Strong Confidence
78	Sooma Medical	At-home depression brain stimulation	$15M–$22M	Partial Confidence	Comparables-Based Estimate	Estimated	$7M	Partial Confidence
79	OpenBCI	Open-source EEG research hardware	$12M–$22M	Low Confidence	Comparables-Based Estimate	Estimated	$3M	Partial Confidence
80	Bottneuro	Personalized Alzheimer’s neurostimulation	$12M–$22M	Low Confidence	Comparables-Based Estimate	Estimated	$4M	Partial Confidence
81	Neuro Event Labs	AI-powered seizure monitoring	$12M–$18M	Partial Confidence	Comparables-Based Estimate	Estimated	$9M	Partial Confidence
82	Cahira Technologies	Injectable nanoelectronic neural implants	$10M–$20M	Low Confidence	Proxy-Based Estimate	Estimated	$0M	Low Confidence
83	Neurosteer	Single-channel clinical brain monitoring	$8M–$18M	Low Confidence	Proxy-Based Estimate	Estimated	$0M	Low Confidence
84	Corticale	High-density intracortical neural probes	$8M–$16M	Low Confidence	Comparables-Based Estimate	Estimated	$2M	Partial Confidence
85	Bía Neuroscience	Neurofeedback smart sleep mask	$8M–$15M	Low Confidence	Proxy-Based Estimate	Estimated	$0M	Low Confidence
86	BrainPatch	Non-invasive brain stimulation	$9M–$14M	Partial Confidence	Active Raise Valuation	Implied	$1M	Low Confidence
87	BrainCapture	Affordable mobile EEG diagnostics	$8M–$14M	Low Confidence	Comparables-Based Estimate	Estimated	$2M	Low Confidence
88	BrainBit	Wearable EEG headbands	$6M–$12M	Low Confidence	Proxy-Based Estimate	Estimated	$0M	Low Confidence
89	Brainphonics	EEG-based hearing diagnostics	$5M–$12M	Low Confidence	Comparables-Based Estimate	Estimated	$0M	Low Confidence
90	Naox Technologies	EEG sensors embedded in earbuds	$6M–$9M	Partial Confidence	Comparables-Based Estimate	Estimated	$5M	Strong Confidence
91	Affectable Sleep	Auditory sleep neurostimulation headband	$4M–$10M	Low Confidence	Proxy-Based Estimate	Estimated	$0M	Low Confidence
92	mBrainTrain	Mobile research-grade EEG systems	$4M–$9M	Low Confidence	Proxy-Based Estimate	Estimated	$0M	Strong Confidence
93	Axorus	Photoacoustic vision-restoration contact lens	$4M–$8M	Low Confidence	Proxy-Based Estimate	Estimated	$1M	Full Confidence
94	Pulvinar Neuro	Closed-loop transcranial brain stimulation	$3M–$8M	Low Confidence	Acquisition Value	Estimated	$0M	Low Confidence
95	Cogitat	Thought-controlled virtual-reality interface	$4M–$7M	Low Confidence	Implied Valuation from Raise	Implied	$1M	Low Confidence
96	BrainTrip	EEG dementia screening	$3M–$7M	Low Confidence	Proxy-Based Estimate	Estimated	$0M	Partial Confidence
97	Reach Neuro	Stroke mobility neurostimulation	$3M–$7M	Low Confidence	Proxy-Based Estimate	Estimated	$1M	Low Confidence
98	BRNLIT AI	Personalized neuroadaptive light stimulation	$2M–$6M	Low Confidence	Proxy-Based Estimate	Estimated	$0M	Low Confidence
99	Pixium Vision	Retinal implants restoring vision	$0M–$1M	Strong Confidence	Acquisition Value	Estimated	$89M	Strong Confidence

Key valuation trends in the Brain-Computer interface market

Insights

Neuralink represents roughly one-third of the total midpoint valuation in this Brain-Computer interface ranking, showing how strongly market value is concentrated around one implantable BCI leader.
The 10 most valuable Brain-Computer interface companies capture about 64% of the combined midpoint valuation, while the remaining 89 companies share only around 36%.
The median Brain-Computer interface startup is valued at approximately $60M, making Neuralink’s $9.5B midpoint about 158 times larger than the company at the center of the ranking.
Beacon Biosignals, Zeto, and Omniscient Neurotechnology combine for approximately $1.4B in midpoint valuation after raising $257M, showing the value investors place on EEG data and brain-mapping software.
Nudge, Merge Labs, and Gestala together carry approximately $1.8B in midpoint valuation, suggesting that ultrasound-based Brain-Computer interface technologies are becoming an important alternative to traditional implanted electrodes.
Zeto’s estimated $280M midpoint is about 7.4 times its disclosed funding, making the clinical EEG company one of the strongest capital-efficiency examples among the larger businesses in the ranking.
Iota Biosciences was acquired for approximately 8.5 times its disclosed funding, which highlights the strategic premium that focused implantable bioelectronics intellectual property can attract.
Pixium Vision’s near-zero residual valuation after $89M of historical funding shows the binary risk of neurotechnology development, especially when clinical progress and commercialization do not meet expectations.

A few word about our methodology

As you can see, we built a database that ranks startups in the Brain-Computer interface market based on their current valuation.

Estimating Brain-Computer interface startup valuations is not always straightforward. Many companies do not publicly disclose their valuation, and the available information can vary widely depending on the company and its stage.

To build this ranking, we applied a structured valuation methodology and cross-checked information across multiple reliable sources.

Whenever possible, we relied on direct disclosures. These include announced valuations from completed funding rounds, public filings for listed companies, or official acquisition prices.

When a Brain-Computer interface company is publicly listed, we use its current market capitalization as the reference valuation.

If a company was acquired and no independent valuation can reasonably be estimated today, we use the acquisition price as the main reference point.

When a startup recently raised capital but the valuation was not disclosed, we estimate the implied valuation using typical dilution levels for that stage of fundraising.

In some cases, we also estimate valuations using operating metrics such as revenue, ARR, clinical adoption, regulatory progress, or customer traction, combined with valuation multiples from comparable neurotechnology companies.

When direct financial data is not available, we may rely on carefully selected comparable startups and other signals such as hiring growth, investor quality, product traction, clinical milestones, intellectual property, or regulatory approvals.

All estimates follow a strict evidence hierarchy. Recent funding rounds with announced valuations carry the most weight, followed by public market data, acquisition values, strong operating metrics, and comparable company analysis.

We also carefully evaluate the age of every data point. Recent information carries more weight, while older Brain-Computer interface market data is treated cautiously and adjusted conservatively when necessary.

Whenever information is uncertain or incomplete, we clearly distinguish between confirmed facts and reasonable inferences.

Because valuation data is not always fully public, each startup in the ranking is assigned a confidence level based on the reliability, recency, and consistency of the available evidence.

Full confidence means the valuation is supported by strong and recent evidence. Strong confidence means the estimate is well supported but includes minor inference. Partial confidence means the estimate relies more heavily on indirect signals. Low confidence means available information is limited or inconsistent.

When confidence is lower, we take a more conservative approach by widening the valuation range. This helps reflect the uncertainty and increases the probability that the true valuation falls within the estimated range.

This reflects how we conduct all our research, including the work behind our report covering the Brain-Computer interface market.

In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.

If you want the full detail on a specific valuation estimate, feel free to contact us and we will gladly explain.

Finally, know that we update the dataset once per month, so come back here if you need fresh information.

Related blog posts

- What are the key fundraising trends in the Brain-Computer interface market?

- The most heavily funded startups in the Brain-Computer interface market

- What does funding activity look like in the Brain-Computer interface market?

- A complete overview of funding deals in the Brain-Computer interface market

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.

Back to blog